Annexon Q2 net loss $55.3M; BLA for tanruprubart on track for Q4 2026

Annexon, Inc.

Q2 net loss $55.3M ($0.28/share) vs $49.2M ($0.34) year ago; R&D $46.6M, G&A $10.6M.
Cash $209.2M plus $200M credit facility ($50M drawn) extends runway into 2028.
Tanruprubart BLA submission for GBS expected Q4 2026; EU MAA under review.
Vonaprument Phase 3 ARCHER II adds Month 24 dual primary endpoint; Month 15 data on track Q4 2026.
ANX1502 POC data in CAD expected Fall 2026; Mark Blumenkranz appointed to board.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.